Miracle Touch BR

Product Overview

Miracle Touch BR is a South Korean brightening skin booster from the DEXLEVO Miracle product portfolio. Formulated with three biomimetic peptides—Oligopeptide-50, Oligopeptide-34, and Oligopeptide-51—alongside the XT80 Whitening Boosting Complex, niacinamide, and vitamin C, Miracle Touch BR is commercially positioned for professional aesthetic applications involving uneven skin tone, pigmentation, and skin radiance. The standard product presentation contains five 5 mL vials per box.

Miracle Touch BR belongs to the Miracle Touch series, which includes skin-conditioning formulations developed for different aesthetic objectives. Unlike Miracle Touch Up, which is based on polycaprolactone (PCL) technology, Miracle Touch BR focuses on peptides, vitamins, and ingredients associated with pigmentation-related biological pathways.

Its formulation combines biomimetic peptides with ingredients investigated for their roles in melanogenesis, melanosome transfer, and oxidative stress. This multi-component approach provides the scientific basis for the product's commercial positioning as a brightening and tone-conditioning skin booster.

Miracle Touch BR is supplied as a liquid formulation in individual 5 mL vials. The commonly documented five-vial package provides a total nominal volume of 25 mL.

This TEOSQUARE product page provides professional buyers with information about Miracle Touch BR's composition, ingredient characteristics, packaging, pigmentation-related mechanisms, and regulatory considerations.

Key Features

• Three Biomimetic Peptides: Contains Oligopeptide-50, Oligopeptide-34, and Oligopeptide-51, a peptide combination commercially associated with the regulation of melanin-related pathways.
• XT80 Whitening Boosting Complex: Incorporates a proprietary complex described in product literature as a combination of amino acids and vitamin-related components developed for pigmentation-oriented skin conditioning.
• Niacinamide (Vitamin B3): Contains niacinamide, an ingredient investigated for its ability to reduce melanosome transfer from melanocytes to surrounding keratinocytes.
• Vitamin C: Includes vitamin C, an antioxidant associated with oxidative stress regulation and pigmentation-related biochemical processes.
• Brightening-Focused Formulation: Commercially positioned for skin-tone refinement and the appearance of pigmentation, freckles, age spots, and uneven complexion.
• PCL-Free Product Positioning: Unlike the PCL-based Miracle Touch Up formulation, Miracle Touch BR is identified as a peptide- and antioxidant-focused product rather than a collagen-stimulating PCL formulation.
• 5 mL Vial Presentation: Commonly supplied in boxes containing five 5 mL vials, providing 25 mL per standard commercial package.

Composition & Specifications

Miracle Touch BR is formulated around three biomimetic peptides, the XT80 Whitening Boosting Complex, niacinamide, and vitamin C.

These ingredients have different biochemical characteristics and are associated with distinct stages of pigmentation regulation, antioxidant activity, and skin conditioning.

The complete quantitative composition has not been established from publicly available manufacturer-controlled specifications. Published ingredient descriptions should therefore be distinguished from verified concentration declarations.

Oligopeptide-50

Oligopeptide-50 is a synthetic peptide identified as one of the three principal biomimetic peptides in Miracle Touch BR.

Biomimetic peptides are designed to reproduce or interact with selected biological signaling processes. Depending on their molecular structure, individual peptides may influence cellular communication or enzyme-associated pathways.

Miracle Touch BR commercial materials associate Oligopeptide-50 with the regulation of pigmentation-related processes.

However, the peptide's exact concentration and its independent contribution to the finished product's clinical performance have not been established through publicly available product-specific studies.

Oligopeptide-34

Oligopeptide-34 is a synthetic peptide investigated in cosmetic research involving pigmentation and skin-tone conditioning.

Melanin production is regulated by multiple signaling pathways, including processes involving melanocyte activity and the expression of enzymes required for pigment synthesis.

Certain peptide-based compounds have demonstrated effects on melanogenesis-related pathways in experimental systems.

Miracle Touch BR incorporates Oligopeptide-34 as part of its three-peptide complex. Its inclusion supports the product's pigmentation-oriented formulation concept, but it does not independently establish a particular percentage of melanin reduction.

Oligopeptide-51

Oligopeptide-51 is another synthetic peptide identified in Miracle Touch BR's biomimetic peptide complex.

The manufacturer-associated product descriptions position the combined peptide system as an ingredient group intended to influence melanin-related pathways.

Nevertheless, evidence involving other peptides or experimental pigmentation models cannot automatically establish the clinical activity of Oligopeptide-51 within the finished Miracle Touch BR formulation.

The three biomimetic peptides are identified by name in published Miracle Touch BR product information. Their individual concentrations, complete sequences, and product-specific clinical contributions should be confirmed using manufacturer-issued technical documentation.

XT80 Whitening Boosting Complex

XT80 is a proprietary brightening complex included in Miracle Touch BR.

Commercial product literature describes XT80 as a combination of amino acids and vitamin-related components developed to complement the formulation's pigmentation-oriented ingredients.

The complex is marketed in relation to tyrosinase-associated melanin synthesis and antioxidant-related biochemical pathways.

Tyrosinase is an essential enzyme involved in melanogenesis. It participates in the oxidation of L-tyrosine and L-DOPA during the early stages of melanin production.

Interactions with tyrosinase and related biochemical intermediates are established targets in pigmentation research.

However, the complete composition and concentration of individual XT80 ingredients have not been independently verified. Its presence does not establish clinically demonstrated inhibition of tyrosinase by the finished product.

Niacinamide (Vitamin B3)

Niacinamide, also known as nicotinamide, is a water-soluble form of vitamin B3.

It is widely investigated in dermatological and cosmetic research for its relationship with skin barrier function, pigmentation, and inflammatory signaling.

One of its established pigmentation-related mechanisms involves the inhibition of melanosome transfer from melanocytes to keratinocytes.

Melanosomes are intracellular structures in which melanin is synthesized and stored. Their transfer to surrounding keratinocytes contributes to the visible distribution of pigment in the epidermis.

Research involving topical niacinamide has demonstrated reductions in pigmentation under specific experimental and clinical conditions.

These findings provide ingredient-level scientific context but cannot automatically establish equivalent clinical outcomes for Miracle Touch BR, particularly when the product's niacinamide concentration and authorized application methods are not confirmed.

Vitamin C

Vitamin C is an essential water-soluble nutrient that participates in antioxidant defense and numerous biochemical reactions.

In dermatological research, vitamin C and selected derivatives have been investigated for their effects on oxidative stress and pigmentation-related pathways.

Ascorbic acid can participate in oxidation-reduction reactions involving intermediates of melanogenesis and may influence the biochemical processes associated with melanin formation.

Vitamin C is also involved in collagen biosynthesis as a cofactor for enzymes required during collagen maturation.

However, the physiological functions of vitamin C do not independently establish increased collagen production, clinical skin brightening, or antioxidant protection from the finished Miracle Touch BR formulation.

The exact vitamin C form, concentration, and stability characteristics of Miracle Touch BR should be verified using the original manufacturer-controlled ingredient specifications.

How Miracle Touch BR Is Formulated to Work

Miracle Touch BR is developed around a multi-ingredient brightening concept involving biomimetic peptides, niacinamide, vitamin C, and the XT80 complex.

These ingredients are associated with different stages of pigmentation-related biology. Their individual mechanisms provide a scientific rationale for the formulation, although the clinical performance of the finished product requires separate verification.

Melanin Synthesis and Tyrosinase

Melanin is a naturally occurring pigment produced by melanocytes. It contributes to skin coloration and helps protect tissues from certain effects of ultraviolet radiation.

The production of melanin, known as melanogenesis, involves multiple biochemical reactions.

Tyrosinase is a key enzyme involved in the conversion of L-tyrosine to L-DOPA and the subsequent formation of dopaquinone.

Dopaquinone participates in downstream reactions that contribute to the formation of different melanin pigments.

Miracle Touch BR's peptide system and XT80 complex are commercially positioned around the regulation of melanin-associated pathways.

However, the presence of these ingredients does not independently demonstrate that the finished formulation inhibits tyrosinase activity in human skin.

Melanosome Transfer Regulation

Melanosomes are specialized intracellular structures responsible for melanin synthesis and storage.

Following pigment formation, melanosomes can be transferred from melanocytes to surrounding keratinocytes.

This transfer contributes to the visible pigmentation of the epidermis.

Niacinamide has been investigated for its ability to reduce melanosome transfer in experimental models and topical clinical studies.

This mechanism is distinct from the direct inhibition of tyrosinase activity.

Miracle Touch BR incorporates niacinamide as one component of its pigmentation-oriented ingredient combination.

Antioxidant Activity and Pigmentation

Oxidative stress can influence cellular signaling pathways involved in skin aging, inflammation, and pigmentation.

Reactive oxygen species are generated through normal metabolism and may increase following environmental exposure, including ultraviolet radiation.

Vitamin C participates in antioxidant reactions and has been investigated for its ability to influence oxidative processes associated with pigmentation.

Miracle Touch BR combines vitamin C with other ingredients that are commercially associated with skin-tone conditioning.

The antioxidant properties of vitamin C should not be interpreted as proof that the finished formulation prevents UV-induced skin damage or replaces established photoprotection.

Multi-Ingredient Brightening Concept

Miracle Touch BR is formulated around several complementary areas of pigmentation-related biology.

• Melanogenesis-Related Signaling: The biomimetic peptides are commercially associated with pigmentation-regulating pathways.
• Tyrosinase-Associated Processes: The XT80 complex is positioned around biochemical processes involved in melanin synthesis.
• Melanosome Transfer: Niacinamide has established research relevance to the transfer of melanosomes between melanocytes and keratinocytes.
• Antioxidant Support: Vitamin C contributes antioxidant-related biochemical properties to the formulation concept.

These mechanisms describe ingredient-level research and the commercial formulation concept. They do not establish clinically proven synergy, a specific percentage of pigmentation reduction, or a guaranteed brightening outcome for Miracle Touch BR.

Miracle Touch BR Formulation Characteristics

Miracle Touch BR differs from conventional hyaluronic acid volumizing fillers and PCL-based collagen stimulators in its primary ingredient system.

Its principal commercially documented components are biomimetic peptides, XT80, niacinamide, and vitamin C.

• Pigmentation-Focused Composition: Developed around ingredients associated with melanin-related biological processes and skin-tone conditioning.
• Three-Peptide System: Contains Oligopeptide-50, Oligopeptide-34, and Oligopeptide-51.
• Vitamin-Based Support: Combines niacinamide and vitamin C with the proprietary XT80 complex.
• Liquid Product Presentation: Supplied as a liquid formulation rather than a lyophilized powder.
• Professional Aesthetic Positioning: Marketed for skin-conditioning applications involving uneven complexion, dullness, and the appearance of pigmentation.

Miracle Touch BR should be evaluated as a separate formulation from the PCL-based Miracle products. A shared product family does not establish identical composition, regulatory classification, or clinical effects.

No independent finished-product clinical evidence has been established here for guaranteed treatment of melasma, post-inflammatory hyperpigmentation, age spots, or other diagnosed pigmentation disorders.

Miracle Touch BR vs. Miracle Touch Up

The Miracle Touch series includes two commercially distinct formulations: Miracle Touch BR and Miracle Touch Up.

Miracle Touch BR is based on peptides, antioxidants, and brightening-oriented ingredients, while Miracle Touch Up is associated with DEXLEVO's solubilized PCL technology.

Miracle Touch BR

Miracle Touch BR is the brightening-oriented formulation within the Touch series.

It incorporates three biomimetic peptides, XT80, niacinamide, and vitamin C in a liquid skin-conditioning product.

Its standard commercial presentation contains five 5 mL vials.

Miracle Touch Up

Miracle Touch Up is the PCL-based formulation within the Touch series.

It uses DEXLEVO's solubilized polycaprolactone technology and is commercially positioned around collagen-related tissue responses.

Miracle Touch Up is commonly supplied in five 2 mL vials.

The two products should not be treated as clinically interchangeable or assumed to share the same composition simply because they belong to the same product family.

The documented distinction between the products is their principal ingredient system. Miracle Touch BR should not be described as a 20% PCL formulation, and the 2 mL packaging associated with Miracle Touch Up should not be substituted for the commonly documented 5 mL Miracle Touch BR presentation.

Packaging & Product Presentation

Miracle Touch BR is commonly supplied as a liquid solution in individual 5 mL glass vials.

The standard commercial package contains five vials, providing a total nominal volume of 25 mL.

Some professional suppliers also offer individual vials separately from complete five-vial boxes.

Buyers should verify whether the selected TEOSQUARE product option corresponds to one 5 mL vial or a complete five-vial package.

A limited number of distributor listings describe different vial volumes. However, the 5 mL × 5-vial presentation is consistently identified by multiple South Korean professional suppliers.

The original product label should be inspected to confirm the product name, fill volume, complete ingredient declaration, batch number, expiration date, and responsible manufacturing entity.

The 5 mL vial volume is a packaging specification, not a recommended administration quantity. Exact commercial contents must be verified against the supplied product.

Storage & Handling

Miracle Touch BR should be stored according to the original manufacturer-issued labeling for the specific supplied product.

Published distributor information is inconsistent regarding the precise storage temperature. Some suppliers describe room-temperature storage, while others recommend refrigeration.

Consequently, a single validated storage temperature range cannot be assigned to all Miracle Touch BR commercial presentations without confirmation from the responsible manufacturer.

• Storage Temperature: Follow the temperature range stated on the original manufacturer label.
• Light Protection: Protect the product from direct sunlight and environmental conditions that may compromise formulation stability.
• Original Packaging: Keep the product in its original sealed container and packaging until required for authorized professional use.
• Container Integrity: Inspect the vial and closure for visible damage, leakage, or signs of compromised packaging integrity.
• Handling After Opening: Follow the manufacturer's original handling instructions. Do not assume that unused contents can be retained for subsequent procedures.
• Product Traceability: Confirm the product identity, lot number, expiration date, and manufacturer information.

Storage temperature, shelf life, and handling requirements should be verified for the exact supplied formulation. Third-party storage recommendations are not a substitute for validated manufacturer instructions.

Safety & Regulatory Considerations

Miracle Touch BR is commercially marketed as a professional brightening skin booster. Its legal classification, approved administration methods, and permitted applications must be verified through the original product documentation and applicable national regulations.

Ingredient-Related Considerations

Miracle Touch BR contains multiple reported ingredients, including synthetic peptides, niacinamide, vitamin C, and the XT80 complex.

Individual ingredients may cause irritation, hypersensitivity, or other reactions depending on their concentration, formulation, and route of exposure.

The complete quantitative ingredient declaration should be reviewed before any professional consideration of the product.

Potential Procedure-Related Risks

Commercial materials describe Miracle Touch BR in the context of professional mesotherapy and skin-conditioning applications.

However, the appearance of injection-related instructions in promotional materials does not independently establish that the finished product is authorized for injection in a particular jurisdiction.

Depending on the legally permitted administration method, potential complications may include localized irritation, redness, swelling, bruising, infection, allergic reactions, and inflammatory responses.

Needle-based procedures can also introduce additional risks associated with tissue injury and infection.

Clinical Evidence Limitations

Niacinamide, vitamin C, and certain peptides have been investigated in pigmentation-related research.

However, much of the available clinical evidence concerns specific topical formulations, experimental peptide systems, or individual ingredients rather than the finished Miracle Touch BR product.

Results obtained from these studies cannot automatically establish equivalent outcomes for Miracle Touch BR.

Claims of guaranteed pigmentation removal, clinically proven melasma treatment, immediate brightening, zero adverse reactions, or results lasting a specified number of months require adequate finished-product clinical evidence.

Pigmentation Disorders and Medical Assessment

Changes in skin pigmentation can result from multiple underlying causes, including ultraviolet exposure, inflammation, hormonal influences, medications, and dermatological conditions.

Melasma, post-inflammatory hyperpigmentation, solar lentigines, and other pigmentary conditions have different biological characteristics and may require different medical approaches.

Miracle Touch BR's brightening-oriented commercial positioning does not establish that it is an approved treatment for these conditions.

Regulatory Authorization

Miracle Touch BR is associated with the South Korean DEXLEVO aesthetic product portfolio.

However, current product-specific authorization as an injectable medicine or medical device has not been independently established for all destination markets.

US FDA approval for Miracle Touch BR has not been established. Regulatory approval of another peptide formulation, cosmetic ingredient, or product within the Miracle range does not automatically establish approval for Miracle Touch BR.

Professional buyers should verify the legal product classification, complete manufacturer documentation, permitted administration route, import eligibility, and applicable professional-use requirements before procurement.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish individual patient suitability, or authorize administration of an unapproved product.

Frequently Asked Questions